Learn More
Gibco™ Human G-CSF Recombinant Protein, PeproTech®
Recombinant Protein
Marke: Gibco™ 300-23-10UG
192.95 CHF gültig bis 2025-06-30
Benutzen Sie den Promotions-Code "24074" um Ihren Promotions-Preis zu erhalten.
Beschreibung
Recombinant Human G-CSF is an 18.7 kDa protein consisting of 174 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
G-CSF (Granulocyte colony stimulating factor) is a naturally occurring cytokine that stimulates the production and antibacterial function of neutrophils and monocytes. Human G-CSF is an 18.8 kDa protein containing 175 amino acid residues, and a soluble isoform of the G-CSF receptor has been described. The pleotropic cytokine is produced by activated monocytes, macrophages, endothelial cells, fibroblasts, astrocytes, osteoblasts and bone marrow cells. G-CSF has been shown to have specific effects on the proliferation, differentiation and activation of hematopoietic cells. G-CSF is also expressed by various transformed cells such as carcinoma cells and myeloblastic leukemia cells. G-CSF is encoded by two distinct DNA sequences, resulting in a full size, high activity and a shorter, low activity isoform of G-CSF. G-CSF is highly conserved among species and has been shown to exert its biological functions through interaction with its receptor expressed on the surface of hematopoietic progenitors, neutrophilic granulocytes and certain carcinoma cell lines. Clinical use of G-CSF has been approved for several therapeutic applications, treatment of neonatal infections, therapy of acute myocardial infarction, granulocyte transfusion in patients with neutropenia, in severe infections and sepsis, therapy in chronic autoimmune neutropenia, treatment of acute myeloid leukemias, Sweet's syndrome and AIDS. Further, G-CSF has been shown to be a marker protein for different carcinomas such as bladder cancer and dysfunction of the protein has been linked to Kostmann Syndrome.
Spezifikation
P09919 | |
protein with no preservative | |
18.7 kDa | |
10 μg | |
RUO | |
C17orf33; colony stimulating factor 3; colony stimulating factor 3 (granulocyte); CSF 3; CSF3; CSF3OS; Csfg; filgrastim; GCSF; G-CSF; Granulocyte colony-stimulating factor; granulocyte-colony stimulating factor; gsf3; lenograstim; MGC45931; MGI-IG; Pluripoietin; RP23-395E10.4 | |
Csf3 | |
Unconjugated | |
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRH LAQP | |
E. coli | |
≥ 98% by SDS-PAGE gel and HPLC analyses. |
ELISA, Functional Assay, Western Blot | |
1440 | |
Human G-CSF | |
E. coli | |
<1 EU/ μg | |
G-CSF | |
The ED50 as determined by the dose-dependent stimulation of the proliferation of murine NFS-60 cells is ≤ 0.1 ng/ml, corresponding to a specific activity of ≥ 1 x 10^7 units/mg | |
Recombinant | |
-20°C | |
Lyophilized |
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.